Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Product Details

Additional Information about Patents

• Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
• Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
• As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N216986

Product 005
GADOPICLENOL (ELUCIREM) SOLUTION 14.553GM/30ML (485.1MG/ML)

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
005	8114863	09/19/2028	DS				11/28/2022
005	10973934	08/06/2039	DS				11/28/2022
005	11590246	01/17/2040		DP			03/27/2023

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration
005	NCE	09/21/2027

 

 

View a list of all patent use codes
View a list of all exclusivity codes